Substance / Medication

Propofol

Overview

Active Ingredient
propofol
RxNorm CUI
8782

Indications

Propofol injectable emulsion is an intravenous general anesthetic and sedation drug indicated for: Limitations of Use Pediatric Use (8.4) [see] Propofol injectable emulsion is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations. Pediatric Use (8.4) [see] Safety, effectiveness and dosing guidelines for propofol injectable emulsion have not

Labeler: Hospira, Inc.Updated: 2025-12-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Propofol injectable emulsion is contraindicated in patients with a known hypersensitivity to propofol or any of propofol injectable emulsion components. Propofol injectable emulsion is contraindicated in patients with a history of anaphylaxis to eggs, egg products, soybeans or soy products.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

46 trials linked to this intervention

46
Total Trials
12
Recruiting
12
With Results

Research Evidence

Published studies and systematic reviews

Sort:
A meta-analysis and systematic review based on perioperative management of elderly patients: is ciprofol an alternative to propofol?
Chen Wei, Xu YuGuang, Zeng YaFei et al. · Eur J Clin Pharmacol · 2025
PMID: 39565391Meta-Analysis
Safety and efficacy of ciprofol versus propofol for gastrointestinal endoscopy: a meta-analysis.
Cheng Xi, Zhang Pengyu, Jiang Dan et al. · BMC Gastroenterol · 2025
PMID: 40033212Meta-AnalysisFull text (PMC)
The Role of Propofol in Alcohol Withdrawal Syndrome: A Systematic Review.
Shirk Logan, Reinert Justin P · J Clin Pharmacol · 2025
PMID: 39415533Meta-AnalysisFull text (PMC)
Postoperative delirium under general anaesthesia by remimazolam versus propofol: A systematic review and meta-analysis of randomised controlled trials.
Suga Masafumi, Yasuhara Jun, Watanabe Atsuyuki et al. · J Clin Anesth · 2025
PMID: 39832842Meta-Analysis
Comparison of the safety of remimazolam and propofol during general anesthesia in elderly patients: systematic review and meta-analysis.
Liu Xianchun, Zhang Longyi, Zhao Li et al. · Front Med (Lausanne) · 2025
PMID: 39991057Meta-AnalysisFull text (PMC)
Intravenous lidocaine with propofol-based sedation for colonoscopy: a systematic review and meta-analysis with trial sequential analysis.
Barbosa Eduardo C, Aguirre Júlia M, Bertoldi Paulo F E et al. · Anaesthesia · 2025
PMID: 40102176Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Propofol (substance)
SNOMED CT
387423006
UMLS CUI
C0033487
RxNorm CUI
8782
Labeler
Hospira, Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
46
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.